Complementary use of passive surveillance and Mini-Sentinel to better characterize hemolysis after immune globulin

Transfusion

Volumn 55, Issue , 2015, Pages S28-S35

  Winiecki, Scott ^a   Baer, Bethany ^a   Chege, Wambui ^a   Jankosky, Christopher ^a   Mintz, Paul ^a   Baker, Meghan ^b,c   Woodworth, Tiffany ^b   Nguyen, Michael ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b HARVARD PILGRIM HEALTH CARE INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR;

DRUG EFFECTS; DRUG SURVEILLANCE PROGRAM; FACTUAL DATABASE; FEMALE; FOOD AND DRUG ADMINISTRATION; FREEZE DRYING; HEMOLYSIS; HUMAN; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SENTINEL SURVEILLANCE; UNITED STATES;

DATABASES, FACTUAL; FEMALE; FREEZE DRYING; HEMOLYSIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PHARMACOVIGILANCE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SENTINEL SURVEILLANCE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84942465461     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/TRF.13116     Document Type: Article

References (29)

1. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991;325: 110-7.
2. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117(4 Suppl):S525-53.
3. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012;367:2015-25.
4. CBER-regulated products: current shortages [Internet]. Silver Spring (MD): US Food and Drug Administration; last updated 2015 Jan 30 [cited 2014 Oct 20]. Available from: http://www.fda.gov/biologicsbloodvaccines/safetyavailabil-ity/shortages/ucm351921.htm
5. Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang 2010;98:12-28.
6. Bellac CL, Polatti D, Hottiger T, et al. Anti-A and anti-B haemagglutinin levels in intravenous immunoglobulins: are they on the rise? A comparison of four different analysis methods and six products. Biologicals 2014;42:57-64.
7. Kahwaji J, Barker E, Pepkowitz S, et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009;4:1993-7.
8. Copelan EA, Strohm PL, Kennedy MS, et al. Hemolysis following intravenous immune globulin therapy. Transfusion 1986;26:410-2.
9. Wilson JR, Bhoopalam H, Fisher M. Hemolytic anemia asso-ciated with intravenous immunoglobulin. Muscle Nerve 1997;20:1142-5.
10. Daw Z, Padmore R, Neurath D,et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008; 48:1598-601.
11. Taylor E. Intravenous immune globulin (IGIV): hemolytic reactions [Internet]. Canadian Adverse Reaction Newsletter 19[4]. Ottawa: Health Canada; c2009 [cited 2014 Oct 21]. Available from: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v19n4-eng.php#a1.
12. FDA adverse event reporting system (FAERS) [Internet]. Silver Spring (MD): US Food and Drug Administration; last updated 2014 Sep 8 [cited 2014 Sep 18]. Available from: http://www.fda.gov/drugs/guidancecomplianceregulatoryin-formation/surveillance/adversedrugeffects
13. Chrischilles EA, Winiecki SK, Fireman B, et al. Mini-Sentinel assessment protocol. Thromboembolic events after immu-noglobulin administration. Version 2 [Internet]. Washington (DC): US Department of Health & Human Services; 2014 Apr 22 [cited 2014 Oct 20]. Available from: http://www.mini-sen-tinel.org/work_products/assessments/Mini-Sentinel_ Thromboembolic-Events-After-Immunoglobulin-Adminis-tration-Protocol.pdf
14. Padmore RF. Hemolysis upon intravenous immunoglobulin transfusion. Transfus Apher Sci 2012;46:93-6.
15. Forrow S, Campion DM, Herrinton LJ, et al. The organiza-tional structure and governing principles of the Food and Drug Administration’s Mini-Sentinel pilot program. Pharma-coepidemiol Drug Saf 2012;21 Suppl 1:12-7.
16. Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment [Internet]. Rock-ville (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER); 2005 [cited 2014 Oct 21]. Available from: http://www.fda.gov/downloads/RegulatoryInforma-tion/Guidances/ucm126834.pdf
17. Platt R, Carnahan RM, Brown JS, et al. The US Food and Drug Administration’s Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf 2012;21 Suppl 1:1-8.
18. Potential signals of serious risks/new safety information identified from the FDA Adverse Event Reporting System (FAERS) [Internet]. Silver Spring (MD): US Food and Drug Administration; last updated 2014 Sep 25 [cited 2014 Oct 21]. Available from: http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/ adversedrugeffects/ucm082196.htm
19. Moride Y, Abenhaim L. Evidence of the depletion of suscep-tibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994;47:731-7.
20. Thorpe SJ, Fox BJ, Dolman CD, et al. Anti-A and anti-B activity in batches of different intravenous immunoglobulin products determined using a direct haemagglutination method. Biologicals 2005;33:111-6.
21. Rajabally YA, Simpson BS, Beri S, et al. Epidemiologic vari-ability of chronic inflammatory demyelinating polyneurop-athy with different diagnostic criteria: study of a UK population. Muscle Nerve 2009;39:432-8.
22. Iijima M, Koike H, Hattori N, et al. Prevalence and incidence rates of chronic inflammatory demyelinating polyneurop-athy in the Japanese population. J Neurol Neurosurg Psychi-atry 2008;79:1040-3.
23. Yuki N, Hartung HP. Guillain-Barre syndrome. N Engl J Med 2012;366:2294-304.
24. Holman RC, Curns AT, Belay ED, et al. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pedia-trics 2003;112(3 Pt 1):495-501.
25. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110:2747-71.
26. Urgent: voluntary market withdrawal—September 23, 2010 Octagam [Immune Globulin Intravenous (Human)] 5% Liq-uid Preparation [Internet]. Silver Spring (MD): US Food and Drug Administration; 2010 Sep 23 [cited 2014 Oct 22]. Available from: http://www.fda.gov/biologicsbloodvaccines/safe-tyavailability/recalls/ucm227133.htm
27. Public Law 110-85 [Internet]. Washington (DC): US Govern-ment Publishing Office; 2007 Sep 27 [cited 2014 Oct 22] Available from: www.gpo.gov/fdsys/pkg/PLAW-110publ85/ pdf/PLAW-110publ85.pdf
28. FDA safety communication: new boxed warning for throm-bosis related to human immune globulin products [Inter-net]. Silver Spring (MD): US Food and Drug Administration; 2013 Nov 14 [cited 2014 Oct 22]. Available from: http://www. fda.gov/biologicsbloodvaccines/safetyavailability/ucm375096.htm
29. Potential signals of serious risks/new safety information identified by the Adverse Event Reporting System (AERS) between January-March 2012 [Internet]. Silver Spring (MD): US Food and Drug Administration; last updated 2014 Jul 10 [cited 2014 Oct 22]. Available from: http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveil-lance/adversedrugeffects/ucm307608.htm